Clinical Trials on Allogenic Bone Marrow Transplantation in Switzerland

Total 86 results

University of Zurich

Completed

Caphosol® Versus State-of-the-art Mouthcare in Patients With Allogeneic Stem Cell Transplantation: a Randomized Controlled Study About the Efficacy of the Mouth Rinse Caphosol®

Allogeneic Stem Cell Transplantation

Switzerland
University Hospital, Geneva

Recruiting

Precision Dosing of Busulfan in Children Undergoing HSCT (BuGenes01)

Allogeneic Hematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation | Autologous Hematopoietic Stem Cell Transplantation

Switzerland
University Hospital, Basel, Switzerland

Completed

Role of Interferon-λ and Vaccine Response

Allogeneic Stem Cell Transplantation | Vaccine Response Impaired

Switzerland
University of Zurich

Completed

Detection of Bone Marrow Changes: Comparison of MRI and DECT

Bone Marrow Changes

Switzerland
University Hospital, Basel, Switzerland

Completed

Comparison of a Powered Bone Marrow Biopsy Device With a Manual System

Bone Marrow Biopsy

Switzerland
University Hospital, Basel, Switzerland

Completed

Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial

Osteonecrosis of the Knee | Bone Marrow Edema of the Knee

Switzerland
European Society for Blood and Marrow Transplantation
Genzyme, a Sanofi Company

Completed

Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia (RATGAA07)

Aplastic Anemia

Switzerland, United Kingdom, Germany, Italy, France, Saudi Arabia
University Hospital, Basel, Switzerland
Novartis; ProPatient foundation of the University Hospital Basel

Completed

Electronic Patient-reported Outcome Monitoring in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria (ePRO-AA-PNH)

Aplastic Anemia | Paroxysmal Nocturnal Hemoglobinuria

Switzerland
Kantonsspital Winterthur KSW
Krebsforschung Schweiz, Bern, Switzerland

Recruiting

Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases (SMILE)

Pain | Bone Metastases | Radiation Therapy

Switzerland
Dr Yan Beauverd

Completed

Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure (MPNClot)

Polycythemia Vera | Thrombocythemia, Essential

Switzerland, United Kingdom
Sana Boudabbous

Recruiting

Pain Relief in Symptomatic Bone Metastases With Adjuvant Hyperthermia MR Guided HIFU (BM-RT-HIFU)

MRI | Pain | Bone Metastases | Radiotherapy

Switzerland
Valentina Garibotto
University Hospital, Geneva

Completed

18F-NaF-PET/MR vs 99mTc-MDP-SPECT/CT to Detect Bone Metastases in Prostate Cancer Patients.

Prostate Cancer | Bone Metastases

Switzerland
University Hospital, Basel, Switzerland

Recruiting

Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

Switzerland
University Hospital, Basel, Switzerland

Enrolling by invitation

CSS-Assessing the Course of Degenerative Cervical Spinal Stenosis Using Functional Outcomes

Cervical Myelopathy | Cervical Spinal Stenosis

Switzerland
European Society for Blood and Marrow Transplantation
Novartis; Pfizer

Completed

hATG+CsA vs hATG+CsA+Eltrombopag for SAA (RACE)

Severe Aplastic Anemia

Switzerland, Netherlands, France, Italy, Spain, United Kingdom
European Society for Blood and Marrow Transplantation
CHUGAI sanofi-aventis

Terminated

Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF) (SAA-G-CSF)

Aplastic Anaemia

France, Netherlands, Germany, United Kingdom, Switzerland, Italy, Sweden, Greece, Czechia
Swiss Group for Clinical Cancer Research

Completed

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm

Switzerland
Geron Corporation

Completed

Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (ET/PV)

Polycythemia Vera | Essential Thrombocythemia

United States, Germany, Switzerland
American College of Radiology - Image Metrix
World Molecular Imaging Society

Unknown

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Bone Metastases

United States, Australia, Austria, Portugal, Switzerland
Novartis Pharmaceuticals

Completed

Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Chronic Myeloid Leukemia With T315I Mutation

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia

Leukemia

Switzerland
University Hospital Freiburg

Completed

Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment

Myelodysplastic Syndromes | Fanconi Anemia | Dyskeratosis Congenita | Pearson Marrow-pancreas Syndrome | Shwachman-diamond Syndrome

Spain, Germany, Switzerland, Austria, Netherlands, Italy, Czech Republic, Belgium, Denmark, Ireland
GWT-TUD GmbH
Celgene

Recruiting

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. (LUSPLUS)

Myelodysplastic Syndromes

Austria, Germany, Spain, Switzerland
European Society for Blood and Marrow Transplantation
Bristol-Myers Squibb

Terminated

Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia (Dasatinib)

Chronic Myeloid Leukemia

Switzerland, United Kingdom, France, Germany
Novartis Pharmaceuticals

Active, not recruiting

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE)

Myelofibrosis

United Kingdom, Australia, Canada, Switzerland, Netherlands, Spain, Germany, Italy, Turkey, Russian Federation, Sweden, Denmark, Hungary
European Organisation for Research and Treatment...

Unknown

Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Anemia

Belgium, Switzerland, Czech Republic, Portugal, Austria, Netherlands, Slovakia
European Working Group of MDS in Childhood

Unknown

Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia

Germany, Austria, Switzerland, Czech Republic, Netherlands, Denmark, Belgium, Italy, Poland
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Myelodysplastic Syndromes | Leukemia

United States, Switzerland
Molecular Partners AG

Recruiting

Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Leukemia | Acute | Relapsed | Myeloid

Netherlands, France, Lithuania, Switzerland
European Organisation for Research and Treatment...

Completed

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

Belgium, Switzerland, Netherlands, Germany
Incyte Corporation

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

MPN (Myeloproliferative Neoplasms)

United States, France, United Kingdom, Spain, Canada, Japan, Germany, Switzerland, Belgium, Austria, Italy
Omeros Corporation

Recruiting

Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Switzerland, Germany, Ukraine, United Kingdom
Omeros Corporation

Recruiting

Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab

Paroxysmal Nocturnal Hemoglobinuria

Germany, Greece, Switzerland, United Kingdom
European Organisation for Research and Treatment...

Withdrawn

Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome

Myelodysplastic Syndromes

France, Netherlands, Norway, Belgium, Switzerland, Austria, United Kingdom, Germany, Denmark
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Switzerland, France
Radboud University Medical Center

Recruiting

A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes (EUMDS)

Myelodysplastic Syndromes (MDS)

Denmark, Switzerland, Serbia, Austria, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Netherlands, Poland, Portugal, Romania, Spain, Sweden, United Kingdom
University Hospital, Basel, Switzerland

Completed

NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Lymphoma | Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Neuroblastoma | Rhabdomyosarcoma

Switzerland, Germany
AbbVie

Active, not recruiting

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Puerto Rico, Russian Federation, Serbia, South... and more
Shire

Completed

Pediatric Disease Registry in Essential Thrombocythaemia (ET)

Essential Thrombocythemia (ET)

United Kingdom, Italy, Czechia, France, Germany, Greece, Spain, Switzerland
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
Amgen

Completed

Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

MDS

Germany, Italy, Belgium, Czechia, Switzerland, France, Austria, Greece, Spain
Alexion Pharmaceuticals

Completed

Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study

Paroxysmal Nocturnal Hemoglobinuria | PNH

Australia, France, United Kingdom, Belgium, Germany, Netherlands, Ireland, United States, Switzerland, Italy
Celgene Corporation

Completed

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, Denmark, Australia, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

United States, Germany, United Kingdom, Italy, France, Switzerland
Geron Corporation

Active, not recruiting

Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States, Canada, Belgium, Spain, Czechia, Korea, Republic of, United Kingdom, Netherlands, Israel, Germany, Russian Federation, Switzerland, Italy, France, Turkey, Poland, Ukraine
University of Jena

Completed

TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study (TIGER)

Chronic Myeloid Leukemia

Germany, Switzerland, Czechia
Heidelberg University

Completed

Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia

Germany, Switzerland
Novartis Pharmaceuticals

Completed

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (TELESTO)

Myelodysplastic Syndromes

China, Hong Kong, Switzerland, United Kingdom, Italy, Thailand, Bulgaria, Greece, Russian Federation, Canada, Mexico, Australia, Denmark, Malaysia, New Zealand, United States
Gilead Sciences

Terminated

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)

Myelodysplastic Syndromes

United States, Spain, Belgium, Australia, France, Hong Kong, Hungary, Finland, New Zealand, Germany, Netherlands, United Kingdom, Italy, Switzerland, Portugal, Canada, Austria, Czechia, Norway, Poland, Turkey

Clinical Trials on Allogenic Bone Marrow Transplantation in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations